These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36064440)

  • 1. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases.
    Douglas CMW; Aith F; Boon W; de Neiva Borba M; Doganova L; Grunebaum S; Hagendijk R; Lynd L; Mallard A; Mohamed FA; Moors E; Oliveira CC; Paterson F; Scanga V; Soares J; Raberharisoa V; Kleinhout-Vliek T
    Orphanet J Rare Dis; 2022 Sep; 17(1):344. PubMed ID: 36064440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Experiences and Made-in-Canada "Social Pharmaceutical Innovations" as Responses to Challenges Facing Drugs for Rare Diseases.
    Douglas CMW
    Healthc Pap; 2023 Jan; 21(1):66-72. PubMed ID: 36692919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustainable rare diseases business and drug access: no time for misconceptions.
    Rollet P; Lemoine A; Dunoyer M
    Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
    Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
    Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare essentials: drugs for rare diseases as essential medicines.
    Stolk P; Willemen MJ; Leufkens HG
    Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China.
    Lee VC; Yao J; Zhang W
    Global Health; 2021 Sep; 17(1):101. PubMed ID: 34488801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
    Jung YL; Hwang J; Yoo HS
    Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape.
    Greenberg A; Kiddell-Monroe R
    Global Health; 2016 Sep; 12(1):54. PubMed ID: 27627882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
    Tafuri G; Bracco A; Grueger J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework.
    Moreno SG; Epstein D
    J Mark Access Health Policy; 2019; 7(1):1583536. PubMed ID: 30956782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.